OVERVIEW

The Review Course is a knowledge-based continuing pharmacy education (CPE) activity designed for pharmacists to acquire factual knowledge. Whether a certification candidate or a currently certified individual, the purpose of the Review Course is to assist the practitioner in developing and maintaining contemporary knowledge and skills. Participants in this course must complete an examination and achieve a score of 70% or greater. Up to two exam attempts are provided to each participant. Successful completion of the course also requires the completion of a course evaluation. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at https://aapp.org/mycpnp/transcript/acpe. Learning Objectives: - Describe the signs and symptoms, diagnostic criteria, and pathophysiology for neurodevelopmental, disruptive, impulse-control, and conduct disorders, including the listing of medications, substances, and diseases that can cause or worsen the psychiatric symptoms for these disorders. - Explain the use of common rating scales for the screening, diagnosis, and monitoring of neurodevelopmental, disruptive, impulse-control, and conduct disorders. - Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of neurodevelopmental, disruptive, impulse-control, and conduct disorders. - Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for drugs used in neurodevelopmental, disruptive, impulse-control, and conduct disorders. - Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for neurodevelopmental, disruptive, impulse-control, and conduct disorders. - Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient. - Outline a plan for monitoring and managing the safety and efficacy of drug therapy. - Describe the management of neurodevelopmental, disruptive, impulse-control, and conduct disorders in special populations (e.g., pregnancy/lactation, children, and older adults). - Recognize the behavioral phenotypes, major medical complications, risk factors, pathogenesis, clinical course, and drug therapy treatment options for patients with the following syndromes: Down Syndrome, Prader-Willi Syndrome, Fragile X Syndrome, Klinefelter’s Syndrome, Rett's Syndrome. - Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with neurodevelopmental, disruptive, impulse-control, and conduct disorders.

KEY DATES

Event Start Date
01 Jan, 2026
Event Start Date
Event End Date
31 Dec, 2027
Event End Date
Credits

The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The 2026-2027 Psychiatric Pharmacotherapy Review Course is a knowledge-based course and will provide 20 hours of continuing education credit.

ACPE Contact Hours: 1.0 ACPE Numbers: 0284-0000-26-007-H01-P (Knowledge) Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content.

Contact Hours: 20 hours of continuing education credit.

  • 20 Contact Hours
  • TARGET AUDIENCE

    PharmacistNurse PractitionerPhysicianAdvanced Practice ProvidersPrimary CliniciansFellows

    SPECIALITIES

    Psychiatric PharmacyNeurologyPharmacologyPsychiatry and Neurology

    SUGGESTED HOTELS

    CONFERENCE VENUE

    LocationTBD

    RELATED CONFERENCES & LIVE WEBINARS